End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.85 USD | -0.51% | -1.20% | -3.43% |
Jul. 03 | Johnson & Johnson's Rybrevant Approved by Health Canada to Treat Advanced Lung Cancer | MT |
Jul. 03 | Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval | DJ |
Financials (USD)
Sales 2024 * | 88.75B | Sales 2025 * | 92.26B | Capitalization | 353B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 3.97 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.82 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 131,900 |
Yield 2024 * |
3.29% | Yield 2025 * |
3.44% | Free-Float | 77.08% |
Latest transcript on Johnson & Johnson
1 day | -0.51% | ||
1 week | -1.20% | ||
Current month | -1.20% | ||
1 month | -2.48% | ||
3 months | -7.94% | ||
6 months | -10.86% | ||
Current year | -3.43% |
Managers | Title | Age | Since |
---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 88-12-31 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 97-12-31 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 19-11-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 19-04-24 |
D. Davis
BRD | Director/Board Member | 72 | 14-06-18 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 09-10-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-07-05 | 9.85 | -0.51% | 167 |
24-07-04 | 9.9 | -0.20% | 592 |
24-07-03 | 9.92 | +1.22% | 568 |
24-07-02 | 9.8 | 0.00% | 811 |
24-07-01 | 9.8 | -1.71% | 911 |
End-of-day quote Buenos Aires S.E., July 04, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
+56.89% | 823B | |
+39.52% | 627B | |
+15.99% | 320B | |
+7.92% | 295B | |
+13.74% | 239B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 167B | |
-2.57% | 159B |
- Stock Market
- Equities
- JNJ Stock
- JNJD Stock